Twenty years ago, a paper in Seminars in Speech and Language described a new way to think about speech treatment in Parkinson’s disease: use principles of neuroplasticity to drive lasting change in voice and communication. That work grew out of clinical research in the late 1980s at the Lee Silverman Center for Parkinson’s in Scottsdale, Arizona, where Dr. Lorraine Ramig and speech-language pathologist Carolyn Mead Bonotati focused on a simple question: could intensive, targeted voice training help the brain reorganize itself to support better communication?
Today, as Parkinson’s cases are projected to reach about 25 million globally by 2050, that question matters more than ever. Up to 90% of people with Parkinson’s experience changes in speech and voice including a soft, monotone voice and mumbled speech. Many people don’t realize how quiet they’ve become until others struggle to hear them. Over time, the frustration of being asked to repeat yourself can lead to speaking less, avoiding phone calls, and withdrawing from social situations which can take a real toll on relationships and quality of life.
Why neuroplasticity matters in Parkinson’s
Neuroplasticity is the brain’s ability to adapt and reorganize in response to training and experience. Even in the context of a neurodegenerative condition like Parkinson’s disease, appropriately designed exercise can strengthen remaining neural pathways and recruit compensatory networks that support better function.
When we published our 2006 article, we focused on five key principles of neuroplasticity that made LSVT LOUD (Lee Silverman Voice Treatment) successful. Today we understand that these five principles are representative of a much broader and more complex set of neuroplasticity mechanisms. Kleim and Jones would go on to articulate ten principles that drive activity dependent neuroplasticity in their 2008 framework, and research continues to uncover additional factors that influence the brain’s capacity to change.
But the core principles we identified through our clinical work with LSVT LOUD remain foundational to understanding why this approach creates lasting brain changes:
1. Intensity Matters
Your brain needs intensive, high‑effort practice to drive change. This isn’t a casual, once or twice a week approach. The intensive dosage, 60-minute sessions, four days a week, for four weeks, with daily home practice provides the repetitions and effort needed to create lasting change.
2. Complexity Builds Capacity
The treatment starts simple, for example speaking single words while seated, and progresses to complex communication like having conversations while walking or ordering coffee in a busy café. This builds automaticity, the ability to use your “loud” voice without thinking about it.
3. Salience – Rewards Drive Change
When you use your loud voice and someone says, “I can hear you better!” or “You sound great!” that’s a neural reward. These positive responses make your brain prioritize the new behavior, cementing the changes and activating motivational circuits in the brain. Further, LSVT LOUD clinicians tailor speech exercises to your interests, so you improve your voice while talking about what matters most to you.
4. Use It or Lose It (And Use It to Improve It)
Inactivity may accelerate decline. But here’s the beautiful part: once you learn to speak loudly in everyday life, on phone calls, at work, in social situations, your daily life becomes continuous exercise. No special equipment or apps are needed.
5. Timing Is Everything
Early intervention matters. The earlier you start, the more potential you have to slow symptom progression and maintain function. Try not to wait until communication becomes severely impaired. That said, improvements can still be made in advanced disease states.
LSVT LOUD: a single target with wide effects
LSVT LOUD is built around one main target: vocal loudness. This focus on vocal loudness is grounded in specific physiological mechanisms—activating the respiratory (breath), phonatory (voice), and articulatory (speech) subsystems while leveraging neuroplasticity principles. The program uses an intensive schedule—60‑minute sessions, four days per week for four weeks—combined with high‑effort voice exercises and carryover into everyday communication.
Although loudness is the focus, research has shown that training healthy vocal loudness can produce broader benefits. Studies document:
- Increased speech intelligibility and improved articulation.
- More animated facial expression.
- Positive changes in swallowing function.
Parkinson’s disease often disrupts a person’s internal “calibration” of effort, so speech that feels “normal” to the individual may actually be much too soft. LSVT LOUD helps recalibrate that sense of effort and loudness, so that a stronger, healthier voice starts to feel normal again.
What’s happening in the brain?
Multiple neuroimaging studies have provided evidence that intensive voice treatment can change how the brain supports speech (see references at end of article). Research using PET and fMRI has shown functional changes after LSVT LOUD, including altered activation in:
- Speech motor networks.
- Right‑hemisphere regions recruited for speech tasks.
- Sensorimotor integration areas.
- Regions involved in self‑monitoring of speech.
These changes support the idea that a focused, amplitude‑based treatment can drive system‑wide reorganization of speech motor control in Parkinson’s disease.
From voice to movement and beyond
The same neuroplasticity principles underlying LSVT LOUD have been extended to body movement with LSVT BIG®, a physical and occupational therapy program that targets larger, more effortful movements. People with Parkinson’s who complete LSVT BIG often demonstrate improvements in gait, balance, reaching, and fine motor skills such as buttoning shirts.
Over time, LSVT LOUD has also been applied to other conditions, including stroke, multiple sclerosis, cerebral palsy, Down syndrome, cerebellar ataxia, and others. Across these populations, intensive, voice‑focused training and sensory recalibration remain central themes.
Digital delivery and access to care
Access to intensive therapy used to be limited by geography, mobility, and scheduling. Advances in telepractice and digital tools have changed that landscape:
- The LSVT Coach software can provide portions of the treatment, helping support practice between clinician visits.
- Ongoing “LOUD for LIFE” and “BIG for LIFE” classes (often virtual) give people opportunities to maintain gains and connect with others.
- LSVT eLOUD delivers treatment via secure telehealth platforms, with studies indicating outcomes comparable to in‑person sessions.
LSVT LOUD was documented to be as effective delivered via telepractice as in-person treatment by Theodoros and colleagues long before COVID. However, telehealth gained momentum during the COVID‑19 pandemic and continues to expand options for people who might otherwise struggle to receive high‑intensity services. Emerging technologies, including generative AI, may further extend clinicians’ ability to coach and support practice over time.
When to seek help and what to expect
Many people with Parkinson’s notice changes in communication long before they seek treatment. Signs that it may be time to talk with a speech-language pathologist include:
- Others frequently ask you to repeat yourself.
- Your voice seems softer, hoarser, or more monotone than before.
- You feel like you’re speaking at a normal volume, but family or friends say they can’t hear you.
- You avoid phone calls or conversations because of communication difficulties.
- Your facial expression seems less animated than it used to be.
If these situations sound familiar, you can:
- Find an LSVT certified clinician. Use the clinician search tool on the LSVT Global website to locate LSVT LOUD or LSVT BIG providers in your region or who offer telehealth services.
- Ask about telehealth. Many clinicians now offer remote treatment options that follow the same standardized LSVT protocol.
- Commit to the protocol. The standard dosage (16 sessions over 4 weeks) is grounded in decades of efficacy and neuroplasticity research. Sixteen hours is a small commitment for the lasting benefit and improved quality of life it provides.
- Plan for maintenance. Regular home practice and periodic “tune‑ups” help sustain gains.
- Review coverage. Many insurance plans, including Medicare in the United States, cover LSVT treatment when speech therapy is medically indicated.
Looking ahead
Epidemiologic projections suggest that by 2030, approximately 1.2 million Americans may be living with Parkinson’s, and global prevalence could reach 25 million by 2050. At the same time, the evidence base for neuroplasticity‑principled treatments such as LSVT LOUD and LSVT BIG continues to grow, including randomized controlled trials and long‑term follow‑up studies.
The core message from the 2006 Seminars in Speech and Language paper still holds: targeted, intensive treatment that leverages the brain’s capacity for change can meaningfully improve communication and movement for people with Parkinson’s and other neurological conditions. Earlier identification, broader access to care (including telepractice), and ongoing support can help more people benefit from these advances.
References
Original reference
Fox, C. M., Ramig, L. O., Ciucci, M. R., Sapir, S., McFarland, D. H., & Farley, B. G. (2006). The science and practice of LSVT/LOUD: Neural plasticity‑principled approach to treating individuals with Parkinson disease and other neurological disorders. Seminars in Speech and Language, 27(4), 283–299. https://doi.org/10.1055/s-2006-955118[2]
Full‑text PDF (LSVT Global resource): https://resources.lsvtglobal.com/hubfs/PDFs/Seminars Fox et al 2006.pdf
Additional imaging references
- Liotti, M., Ramig, L., Vogel, D., New, P., Cook, C., Ingham, R. J., Ingham, J. C., & Fox, P. (2003). Hypophonia in Parkinson’s disease: Neural correlates of voice treatment revealed by PET. Neurology, 60(3), 432–440. https://doi.org/10.1212/wnl.60.3.432
- Narayana, S., Fox, P. T., Zhang, W., Franklin, C., Robin, D. A., Vogel, D., & Ramig, L. O. (2010). Neural correlates of efficacy of voice therapy in Parkinson’s disease identified by performance–correlation analysis. Human Brain Mapping, 31(2), 222–236. https://doi.org/10.1002/hbm.20859
- Baumann, A., Nebel, A., Granert, O., Giehl, K., Wolff, S., Schmidt, W., Baasch, C., Schmidt, G., Witt, K., Deuschl, G., Hartwigsen, G., Zeuner, K. E., & van Eimeren, T. (2018). Neural correlates of hypokinetic dysarthria and mechanisms of effective voice treatment in Parkinson disease. Neurorehabilitation and Neural Repair, 32(12), 1055–1066. https://doi.org/10.1177/1545968318812726
- Narayana, S., Franklin, C., Peterson, E., Hunter, E. J., Robin, D. A., Halpern, A., Spielman, J., Fox, P. T., & Ramig, L. O. (2022). Immediate and long‐term effects of speech treatment targets and intensive dosage on Parkinson’s disease dysphonia and the speech motor network: Randomized controlled trial. Human Brain Mapping, 43(7), 2328–2347. https://doi.org/10.1002/hbm.25790
For those interested in a deeper dive into these neuroimaging findings and the broader science of neuroplasticity in LSVT treatments, watch the webinar: Brain and Body Reboot: Harnessing Neuroplasticity with LSVT LOUD and LSVT BIG.
AI assistance (Claude, Anthropic and Perplexity) was used to help translate the original academic article into blog format and to research current statistics. All content was reviewed, edited, and approved by human author(s).